B.R.A.I.N. Biotechnology Research And Information Network AG, DE0005203947

B.R.A.I.N. Biotechnology Research And Information Network AG, DE0005203947

31.01.2017 - 14:32:17

B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN proposes Supervisory Board candidates for election at its Annual General Meeting

BRAIN proposes Supervisory Board candidates for election at its Annual General Meeting

Zwingenberg, January 31, 2017: Today, B.R.A.I.N. Biotechnology Research and Information Network AG ("BRAIN AG", ISIN DE0005203947 / WKN 520394) has published the invitation for its first public Annual General Meeting as a stock listed company, to be held on March 9, 2017, to its shareholders in the electronic Federal Gazette (Bundesanzeiger) and on its website. Besides other agenda items, four of the six Supervisory Board members of BRAIN AG are to be newly elected during the General Meeting. While the term of office of Professor Klaus-Peter Koller and Dr Holger Zinke regularly ends with the end of the upcoming General Meeting, the Supervisory Board members Siegfried Drueker and Dr Matthias Kromayer resign from their positions. In addition to the re-election of the long-term Supervisory Board member Professor Dr Klaus-Peter Koller, three new Supervisory Board candidates are proposed for election to the Annual General Meeting.

The three new candidates are Dr Anna Eichhorn, Dr Martin Jager and Dr Georg Kellinghusen. In selecting these three, the Supervisory Board has paid particular attention to continuity, experience and necessary expertise, with an additional focus on the indispensable industry, specialist and business knowledge of the candidates, which are essential for the exercise of the impending Supervisory Board mandates.

Dr Anna Eichhorn is an entrepreneur in the field of molecular diagnostics and a proven specialist in the translation of data on human genetics into the development of active ingredients. Dr Martin Jager has extensive and long-standing international experience in the development and marketing of new natural products and food ingredients. The expertise of Dr Georg Kellinghusen as a recognised financial expert is based on his 30 years of CFO work in various listed companies as well as his former membership in the Supervisory Board of BRAIN AG. Furthermore, Professor Dr Klaus-Peter Koller with his industrial expertise at the interface of research, development and production of new biological products will continue to benefit BRAIN.

The election proposals to the Annual General Meeting are consistent with the objectives adopted by the Supervisory Board regarding its composition. In the opinion of the Supervisory Board, all candidates are highly familiar with the sector in which the Company operates.

The Chairman of the Supervisory Board and the entire Management Board of the Company wish to thank Siegfried Drueker, Dr Matthias Kromayer and Dr Holger Zinke, who will leave the BRAIN Supervisory Board at the end of the Annual General Meeting on March 9, 2017, for the long-standing, successful and always trustworthy cooperation.

Further details on the Annual General Meeting as well as on the election proposals for the Supervisory Board are available on the website under www.brain-biotech.de/en/investor-relations/general-meetings.

 

About BRAIN

BRAIN is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. Today, BRAIN's business model is based on two pillars - "BioScience" and "BioIndustrial". The first pillar, "BioScience", comprises its - frequently exclusive - collaboration business with industrial partners. The second pillar "BioIndustrial" comprises the development and commercialisation of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en

Contact: B.R.A.I.N Biotechnology Research And Information Network AG Dr. Martin Langer Executive Vice President Corporate Development Darmstädter Str. 34-36 64673 Zwingenberg, Germany Tel.: +49-6251-9331-16 Fax: +49-6251-9331-11 E-Mail: ir@brain-biotech.de www.brain-biotech.deDisclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

31.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English

Company: B.R.A.I.N. Biotechnology Research And Information Network AG Darmstädter Straße 34-36 64673 Zwingenberg

Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: ir@brain-biotech.de Internet: www.brain-biotech.de ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange   End of News DGAP News Service

540371  31.01.2017 

@ dgap.de

Amazon wird sich schwarzärgern, aber …

… wir schenken Ihnen den Report „Börsenpsychologie - Markttechnik für Trader“ heute trotzdem kostenfrei. Normalerweise kostet der Report im Onlinehandel 39,99 Euro.

Sie können sich den genialen Report heute jedoch absolut kostenfrei sichern. Wir senden Ihnen den Report vollkommen KOSTENFREI zu.

Jetzt HIER klicken und dank richtigen Timing reich an der Börse werden!